Huang et al., (74), suggest that the ratio of the reinvigorated exhausted CTLs to the basic tumor load, positively correlates with clinical response of patients with melanoma to pembrolizumab—another PD-1 blocker—and can serve as a response predictor for this drug. Here, PDCD1 is linked to melanoma.